Indaptus Therapeutics Secures $6 Million Investment Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Source: Globenewswire
Indaptus Therapeutics Inc. experienced a significant price increase of 9.93%, crossing above the 5-day SMA, despite the broader market's decline with the Nasdaq-100 down 0.32% and the S&P 500 down 0.29%.
This surge is attributed to the company's announcement of a $6 million securities purchase agreement with investor David E. Lazar, which includes the issuance of 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock. This investment is expected to bolster the company's capital base and support future strategic developments, alongside a leadership change with Lazar appointed as Co-CEO and Chairman of the Board.
The implications of this investment are significant, as it not only strengthens the company's financial position but also reflects a strategic shift in leadership aimed at enhancing shareholder value and exploring new opportunities in cancer and viral infection treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDP
Wall Street analysts forecast INDP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.500
Low
10.00
Averages
10.00
High
10.00
Current: 4.500
Low
10.00
Averages
10.00
High
10.00
No data
About INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
Investigation into Indaptus Therapeutics Shareholder Claims
- Legal Investigation Initiated: Abbott Cooper PLLC is investigating potential claims on behalf of Indaptus Therapeutics shareholders to determine if the board violated fiduciary duties during a preferred stock private placement prior to December 22, 2025, which could impact shareholder rights.
- Shareholder Rights Protection: The investigation specifically targets shareholders who held Indaptus stock before December 22, 2025, encouraging them to understand their legal rights and take action if necessary to protect their interests.
- No-Risk Consultation: Abbott Cooper PLLC offers consultations at no cost to shareholders, meaning they incur no fees unless recovery is achieved, a strategy designed to lower barriers for shareholder participation in the investigation.
- Potential Legal Consequences: Should the investigation reveal board misconduct, it could lead to legal action against Indaptus, potentially affecting the company's reputation and shareholder returns, prompting shareholders to closely monitor developments.
See More
Biotech Stocks Show Significant Pre-Market Movements
- Significant Pre-Market Gains: Bio Green Med Solution, Inc. (BGMS) surged 182% to $3.01 in pre-market trading, indicating strong market reaction to potential acquisition agreements, which may attract further investor interest.
- Other Gaining Stocks: Clearmind Medicine Inc. (CMND) rose 37% to $4.03, while BioCardia, Inc. (BCDA) increased by 30% to $1.19, suggesting that financing deals are boosting investor confidence in the biotech sector, potentially leading to a surge in subsequent investments.
- Pre-Market Decliners: Indaptus Therapeutics, Inc. (INDP) fell 36% to $3.04, reflecting market concerns over its financial health, which may prompt investors to reassess its future outlook.
- Other Declining Stocks: Zhongchao Inc. (ZCMD) dropped 16% to $0.03, and Aditxt, Inc. (ADTX) decreased by 14% to $0.06, indicating a weakening market confidence in these companies, which could impact their future financing capabilities.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Indaptus Therapeutics Q1 Financial Analysis
- Financial Performance: Indaptus Therapeutics reported a GAAP EPS of -$0.23 for Q1 2026, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company had approximately $1.5 million in cash and cash equivalents, a significant decrease from $8.5 million as of December 31, 2025, highlighting liquidity issues that could hinder business growth.
- Capital Raising Needs: The company must raise additional capital to support its business objectives, with no assurance that such financing will be available on acceptable terms, increasing operational uncertainty and potentially impacting strategic execution.
- Strategic Assessment: Indaptus is evaluating financing alternatives and strategic options to support its corporate strategy, and the effectiveness of this process will directly influence the company's long-term development and market competitiveness.
See More
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, issuing 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, which is expected to bolster the company's capital base and support future strategic developments.
- Leadership Change: David E. Lazar has been appointed Co-CEO and Chairman of the Board, while Jeffrey Meckler will continue as Co-CEO, leading the team to evaluate the company's lead product candidates and explore strategic opportunities aimed at driving shareholder value.
- Board Restructuring: Following the closing of the transaction, the Board was reconstituted with Avraham Ben-Tzvi joining, replacing the resigning Hila Kara and Dr. Robert Martell, reflecting the company's governance adjustments to align with new strategic directions.
- Shareholder Approval: The conversion of shares is contingent upon obtaining shareholder approval at the upcoming meeting expected in Q1 2026, a process that will provide crucial support for the company's future capital structure and shareholder equity.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
Investigation into Indaptus Therapeutics Shareholder Claims
- Legal Investigation Initiated: Abbott Cooper PLLC is investigating potential claims on behalf of Indaptus Therapeutics shareholders to determine if the board violated fiduciary duties during a preferred stock private placement prior to December 22, 2025, which could impact shareholder rights.
- Shareholder Rights Protection: The investigation specifically targets shareholders who held Indaptus stock before December 22, 2025, encouraging them to understand their legal rights and take action if necessary to protect their interests.
- No-Risk Consultation: Abbott Cooper PLLC offers consultations at no cost to shareholders, meaning they incur no fees unless recovery is achieved, a strategy designed to lower barriers for shareholder participation in the investigation.
- Potential Legal Consequences: Should the investigation reveal board misconduct, it could lead to legal action against Indaptus, potentially affecting the company's reputation and shareholder returns, prompting shareholders to closely monitor developments.
See More
Biotech Stocks Show Significant Pre-Market Movements
- Significant Pre-Market Gains: Bio Green Med Solution, Inc. (BGMS) surged 182% to $3.01 in pre-market trading, indicating strong market reaction to potential acquisition agreements, which may attract further investor interest.
- Other Gaining Stocks: Clearmind Medicine Inc. (CMND) rose 37% to $4.03, while BioCardia, Inc. (BCDA) increased by 30% to $1.19, suggesting that financing deals are boosting investor confidence in the biotech sector, potentially leading to a surge in subsequent investments.
- Pre-Market Decliners: Indaptus Therapeutics, Inc. (INDP) fell 36% to $3.04, reflecting market concerns over its financial health, which may prompt investors to reassess its future outlook.
- Other Declining Stocks: Zhongchao Inc. (ZCMD) dropped 16% to $0.03, and Aditxt, Inc. (ADTX) decreased by 14% to $0.06, indicating a weakening market confidence in these companies, which could impact their future financing capabilities.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Indaptus Therapeutics Q1 Financial Analysis
- Financial Performance: Indaptus Therapeutics reported a GAAP EPS of -$0.23 for Q1 2026, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company had approximately $1.5 million in cash and cash equivalents, a significant decrease from $8.5 million as of December 31, 2025, highlighting liquidity issues that could hinder business growth.
- Capital Raising Needs: The company must raise additional capital to support its business objectives, with no assurance that such financing will be available on acceptable terms, increasing operational uncertainty and potentially impacting strategic execution.
- Strategic Assessment: Indaptus is evaluating financing alternatives and strategic options to support its corporate strategy, and the effectiveness of this process will directly influence the company's long-term development and market competitiveness.
See More
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, issuing 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, which is expected to bolster the company's capital base and support future strategic developments.
- Leadership Change: David E. Lazar has been appointed Co-CEO and Chairman of the Board, while Jeffrey Meckler will continue as Co-CEO, leading the team to evaluate the company's lead product candidates and explore strategic opportunities aimed at driving shareholder value.
- Board Restructuring: Following the closing of the transaction, the Board was reconstituted with Avraham Ben-Tzvi joining, replacing the resigning Hila Kara and Dr. Robert Martell, reflecting the company's governance adjustments to align with new strategic directions.
- Shareholder Approval: The conversion of shares is contingent upon obtaining shareholder approval at the upcoming meeting expected in Q1 2026, a process that will provide crucial support for the company's future capital structure and shareholder equity.
See More
